TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions
- Malignant Ovarian Mixed Epithelial Tumor
- Ovarian Brenner Tumor
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Undifferentiated Ovarian Carcinoma
Interventions
- DRUG: TLR8 Agonist VTX-2337
- OTHER: Diagnostic Laboratory Biomarker Analysis
- OTHER: Pharmacological Study
- DRUG: Pegylated Liposomal Doxorubicin Hydrochloride
- DRUG: Paclitaxel
Sponsor
Gynecologic Oncology Group
Collaborators